

Pemetrexed

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

ADJUSTMENTS

Quality of life

QoL data pending

Serious and disabling adverse effects

Less serious adverse events observed

Other adjustments

Pemetrexed

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
 Therapeutic Indication: In combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology
 Experimental Arm: Pemetrexed + Cisplatin
 Control Arm: Cisplatin + gemcitabine



